Your session is about to expire
← Back to Search
Functional Precision Oncology for Breast Cancer Recurrence (TOWARDS-II Trial)
TOWARDS-II Trial Summary
This trial will use a personalized approach to predicting, preventing and treating early metastatic recurrence in breast cancer patients.
TOWARDS-II Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTOWARDS-II Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TOWARDS-II Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I don't have recent severe illnesses like heart attack or liver disease that would prevent me from receiving standard chemotherapy.My breast cancer is triple negative or has low hormone receptors and is HER2 negative.My breast cancer has spread to other parts of my body.I have been cancer-free from another type of cancer for over 5 years.My breast cancer is HER2 positive or HER2 amplified.My cancer in the primary site or lymph nodes is larger than 1.5 cm.My cancer is at an early to mid-stage (Stage I-III).I am willing and able to provide samples from my tumor or affected lymph nodes.I have cancer in both of my breasts.I have not received any cancer treatment or experimental therapy before joining this study.I have not received any treatment for my breast cancer.My cancer tests positive for hormone receptors.I am post-menopausal or not pregnant.I am eligible for or already receiving chemotherapy before surgery as part of my treatment plan or another clinical trial.I can take care of myself and am up and about more than half of my waking hours.I am 18 years old or older.I do not have any severe illnesses that could affect my participation in the study.
- Group 1: Physician Questionnaire
- Group 2: Treatment: All Patients
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any volunteers currently needed for this research?
"The clinical trial in question appears to have closed enrollment, with the last update on the study being from October 20th, 2022. The trial was first posted December 31st, 2022. Although this particular research project is not looking for any more volunteers, there are 3,406 other trials currently enrolling participants."
What are the benefits that researchers hope to gain from this clinical trial?
"The goal of this trial is to compare the recurrence rates of patients whose tumors successfully engrafted in mice (PDX+) with those who did not (PDX-). Secondary outcomes include correlations between tumor engraftment and relapse-free survival, overall survival, response to preoperative chemotherapy and treatment response as assessed on the Residual Cancer Burden scale; correlation between MHCII Immune Activation Score (high vs. low and as a continuous variable) and tumor engraftment; proportion of cases where any type of patient derived models are successfully generated and clinically actionable therapies are identified by functional precision oncology"
What are the risks associated with Functional Precision Oncology treatments?
"There is some evidence backing the safety of this cancer treatment, but none to suggest that it is effective. Therefore, our team has given it a rating of 2."
Share this study with friends
Copy Link
Messenger